TY - JOUR
T1 - Serologic cross-reactions among streptococcal group A, A-variant, and C polysaccharides
AU - Shulman, Stanford T.
AU - Ayoub, Elia M.
N1 - Funding Information:
1 Supported in part by Grants AI 09645 and HL20533 from the National Institutes of Health and by Grant AG315 from the American Heart Association, Florida Affiliate. 2 To whom correspondence should be addressed: Division of Infectious Disease, The Children’s Memorial Hospital, 2300 Children’s Plaza, Chicago, Il. 60614.
PY - 1983
Y1 - 1983
N2 - Serologic cross-reactions among streptococcal groups A, A-variant (A-V), and C cell wall polysaccharides were found previously in studies employing capillary or quantitative precipitin techniques. Similar cross-reactions occur with radioimmune precipitation using extrinsically labeled 125I-streptococcal antigens. This study was performed to determine the degree of cross-reactivity when intrinsically labeled 14C-polysaccharide antigens were used in the radioimmune precipitin assay. Unadsorbed antisera from rabbits immunized with group A streptococci bound 3-5% as much 14C-A-V antigen as homologous A carbohydrate but undetectable amounts of C polysaccharide. Similarly, A-V antisera bound 3-5% as much 14C-A or 14C-C carbohydrate as A-V antigen. Group C antiserum bound 1-2% as much A and A-V antigens as C carbohydrate. Thus, less than 3% of intrinsically labelled 14C-A or 14C-C carbohydrate represents exposed A-V antigenic sites, i.e., exposed polyrhamnose backbone. Otherwise, group A, C, or A-V carbohydrates failed to exhibit heterologous determinants. Anti-peptidoglycan antibodies in antisera did not result in serologic cross-reactivity. These data suggest that formamide-extracted streptococcal group-specific polysaccharides, intrinsically labeled with 14C, may possess greater group specificity than 125I-carbohydrates and yield only negligible cross-reactivity with heterologous antisera. This degree of cross-reactivity does not appear to be sufficient to account for the persistently elevated serum levels of antibody to group A carbohydrate in patients with rheumatic heart disease.
AB - Serologic cross-reactions among streptococcal groups A, A-variant (A-V), and C cell wall polysaccharides were found previously in studies employing capillary or quantitative precipitin techniques. Similar cross-reactions occur with radioimmune precipitation using extrinsically labeled 125I-streptococcal antigens. This study was performed to determine the degree of cross-reactivity when intrinsically labeled 14C-polysaccharide antigens were used in the radioimmune precipitin assay. Unadsorbed antisera from rabbits immunized with group A streptococci bound 3-5% as much 14C-A-V antigen as homologous A carbohydrate but undetectable amounts of C polysaccharide. Similarly, A-V antisera bound 3-5% as much 14C-A or 14C-C carbohydrate as A-V antigen. Group C antiserum bound 1-2% as much A and A-V antigens as C carbohydrate. Thus, less than 3% of intrinsically labelled 14C-A or 14C-C carbohydrate represents exposed A-V antigenic sites, i.e., exposed polyrhamnose backbone. Otherwise, group A, C, or A-V carbohydrates failed to exhibit heterologous determinants. Anti-peptidoglycan antibodies in antisera did not result in serologic cross-reactivity. These data suggest that formamide-extracted streptococcal group-specific polysaccharides, intrinsically labeled with 14C, may possess greater group specificity than 125I-carbohydrates and yield only negligible cross-reactivity with heterologous antisera. This degree of cross-reactivity does not appear to be sufficient to account for the persistently elevated serum levels of antibody to group A carbohydrate in patients with rheumatic heart disease.
UR - http://www.scopus.com/inward/record.url?scp=0020537938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020537938&partnerID=8YFLogxK
U2 - 10.1016/0090-1229(83)90157-5
DO - 10.1016/0090-1229(83)90157-5
M3 - Article
C2 - 6872361
AN - SCOPUS:0020537938
SN - 0090-1229
VL - 28
SP - 229
EP - 242
JO - Clinical Immunology and Immunopathology
JF - Clinical Immunology and Immunopathology
IS - 2
ER -